Guo X, Li C, Cao H, Yang G
World J Clin Cases. 2024; 12(3):657-664.
PMID: 38322452
PMC: 10841960.
DOI: 10.12998/wjcc.v12.i3.657.
Takiar R, Phillips T
Blood Adv. 2023; 7(12):2912-2916.
PMID: 36812691
PMC: 10285534.
DOI: 10.1182/bloodadvances.2022007537.
Rindone G, Aroldi A, Bossi E, Verga L, Zambrotta G, Tarantino S
Blood Adv. 2022; 7(3):314-316.
PMID: 35914224
PMC: 9898594.
DOI: 10.1182/bloodadvances.2022007538.
Zhang K, Wang J, Zhu Y, Liu X, Li J, Shi Z
Front Oncol. 2022; 12:844990.
PMID: 35686089
PMC: 9170954.
DOI: 10.3389/fonc.2022.844990.
Chowdhury Z
Cureus. 2021; 13(8):e16882.
PMID: 34513457
PMC: 8412059.
DOI: 10.7759/cureus.16882.
Molecular Update and Evolving Classification of Large B-Cell Lymphoma.
Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C
Cancers (Basel). 2021; 13(13).
PMID: 34283060
PMC: 8269067.
DOI: 10.3390/cancers13133352.
Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR signaling pathways.
Shijie L, Zhen P, Kang Q, Hua G, Qingcheng Y, Dongdong C
Clin Transl Med. 2021; 11(6):e377.
PMID: 34185412
PMC: 8214859.
DOI: 10.1002/ctm2.377.
Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report.
Zhang M, Jin L, Duan Y, Yang J, Huang S, Jin M
World J Clin Cases. 2021; 9(17):4268-4278.
PMID: 34141790
PMC: 8173411.
DOI: 10.12998/wjcc.v9.i17.4268.
Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors.
Trahair T, Gifford A, Fordham A, Mayoh C, Fadia M, Lukeis R
JCO Precis Oncol. 2020; 3.
PMID: 32914017
PMC: 7446396.
DOI: 10.1200/PO.18.00297.
Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.
Yang J, Li J, Gu W, Jin L, Duan Y, Huang S
World J Clin Cases. 2020; 8(9):1685-1692.
PMID: 32420302
PMC: 7211542.
DOI: 10.12998/wjcc.v8.i9.1685.
Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Wang L, Lui V
Cancers (Basel). 2020; 12(2).
PMID: 32059449
PMC: 7072244.
DOI: 10.3390/cancers12020426.
PROTACs: great opportunities for academia and industry.
Sun X, Gao H, Yang Y, He M, Wu Y, Song Y
Signal Transduct Target Ther. 2019; 4:64.
PMID: 31885879
PMC: 6927964.
DOI: 10.1038/s41392-019-0101-6.
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C, Han X, Yang X, Jiang B, Liu J, Xiong Y
Eur J Med Chem. 2018; 151:304-314.
PMID: 29627725
PMC: 5924614.
DOI: 10.1016/j.ejmech.2018.03.071.
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
Sharma G, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R
Cancers (Basel). 2018; 10(3).
PMID: 29495603
PMC: 5876637.
DOI: 10.3390/cancers10030062.
Relapsed anaplastic lymphoma kinase-positive large B-cell lymphoma expressed cluster of differentiation 4 and cytokeratin: An initially misdiagnosed case corrected by immunoglobulin κ locus gene rearrangement detection.
Shi Y, Li X, Song Y, Zhou L, Feng Q, Wang P
Oncol Lett. 2017; 14(1):787-791.
PMID: 28693234
PMC: 5494706.
DOI: 10.3892/ol.2017.6180.
Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature.
Jiang X, Yu B, Wang W, Zhou X, Li X
PLoS One. 2017; 12(6):e0178416.
PMID: 28665943
PMC: 5493294.
DOI: 10.1371/journal.pone.0178416.
Diagnosis and treatment of CD20 negative B cell lymphomas.
Katchi T, Liu D
Biomark Res. 2017; 5:5.
PMID: 28191314
PMC: 5297138.
DOI: 10.1186/s40364-017-0088-5.
Targeting ALK: Precision Medicine Takes on Drug Resistance.
Lin J, Riely G, Shaw A
Cancer Discov. 2017; 7(2):137-155.
PMID: 28122866
PMC: 5296241.
DOI: 10.1158/2159-8290.CD-16-1123.
ALK: a tyrosine kinase target for cancer therapy.
Holla V, Elamin Y, Bailey A, Johnson A, Litzenburger B, Khotskaya Y
Cold Spring Harb Mol Case Stud. 2017; 3(1):a001115.
PMID: 28050598
PMC: 5171696.
DOI: 10.1101/mcs.a001115.
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.
Mondello P, Pitini V, Barresi V, Brea E, Di Mirto C, Arrigo C
Exp Hematol Oncol. 2016; 5:1.
PMID: 26740908
PMC: 4702294.
DOI: 10.1186/s40164-015-0030-1.